Edgewise to Sell Muscle Disease Business for $1.55 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 01 2026
0mins
Source: PRnewswire
- Significant Transaction Value: Edgewise Therapeutics has entered into an agreement with Servier to sell its muscle disease business for $1.55 billion in upfront cash, with potential milestone payments of up to $1.1 billion, leading to a total potential consideration of $2.65 billion, which will significantly enhance Edgewise's financial flexibility.
- Strategic Focus Shift: Following the transaction, Edgewise will pivot to focus on cardiovascular therapies, developing drugs such as EDG-7500 and EDG-15400, which is expected to accelerate the unlocking of its cardiovascular pipeline's potential and enhance its competitive position in the market.
- Clinical Data Reporting Plans: Edgewise plans to report 12-week data from the CIRRUS-HCM trial in Q2 2026, which will provide critical insights for the further development of its cardiac drugs, thereby advancing its clinical progress.
- Employee Transition Assurance: All Edgewise employees supporting the muscle disease business will receive comparable offers from Servier, ensuring continuity of operations and future commercial execution, reflecting a commitment to talent retention and strategic integration.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EWTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EWTX
Wall Street analysts forecast EWTX stock price to rise
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 34.060
Low
16.00
Averages
38.14
High
51.00
Current: 34.060
Low
16.00
Averages
38.14
High
51.00
About EWTX
Edgewise Therapeutics, Inc. is a muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The Company is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Edgewise Grants Stock Options to New Employees
- Stock Option Grant: On May 29, 2026, Edgewise Therapeutics granted a total of 74,000 inducement stock options to four new non-executive employees, aimed at attracting talent and strengthening the team.
- Exercise Price Setting: Each inducement stock option has an exercise price of $34.16 per share, equal to the closing price of Edgewise common stock on the grant date, ensuring alignment of employee interests with those of shareholders.
- Vesting Arrangement: The vesting schedule for these stock options stipulates that 25% will vest on each employee's one-year anniversary, with the remaining shares vesting monthly, thereby incentivizing continued contributions during employment.
- Compliance Assurance: This stock option grant complies with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's strategic considerations and commitment to attracting and retaining key talent.
See More
Servier Acquires Edgewise's Muscular Dystrophy Operations
- Significant Deal Size: Servier's acquisition of Edgewise Therapeutics' muscular dystrophy operations for $2.65 billion, including the lead drug Sevasemten, is expected to close in Q3 2026, indicating Servier's strategic expansion in rare neuromuscular disorders.
- Stock Surge: Edgewise Therapeutics (EWTX) shares soared over 20% on Monday, potentially marking the largest single-day gain in six months, reflecting strong market sentiment towards the deal, and if it closes at current levels, it could push the stock to a record high.
- Drug Development Outlook: Sevasemten, an investigational oral therapy designed to protect muscles from contraction-related damage, is currently undergoing pivotal trials for Becker muscular dystrophy and a Phase 2 study for Duchenne muscular dystrophy, addressing a significant unmet need in the market with no approved treatments available.
- Positive Safety Data: The MESA extension study indicates that Sevasemten maintained stable physical function in Becker muscular dystrophy patients for up to 3.5 years, with a favorable cardiac safety profile over 12 months, showing improved cardiac function in some patients, thereby enhancing the drug's market appeal.
See More
Edgewise to Sell Muscle Disease Business for $1.55 Billion
- Significant Transaction Value: Edgewise Therapeutics has entered into an agreement with Servier to sell its muscle disease business for $1.55 billion in upfront cash, with potential milestone payments of up to $1.1 billion, leading to a total potential consideration of $2.65 billion, which will significantly enhance Edgewise's financial flexibility.
- Strategic Focus Shift: Following the transaction, Edgewise will pivot to focus on cardiovascular therapies, developing drugs such as EDG-7500 and EDG-15400, which is expected to accelerate the unlocking of its cardiovascular pipeline's potential and enhance its competitive position in the market.
- Clinical Data Reporting Plans: Edgewise plans to report 12-week data from the CIRRUS-HCM trial in Q2 2026, which will provide critical insights for the further development of its cardiac drugs, thereby advancing its clinical progress.
- Employee Transition Assurance: All Edgewise employees supporting the muscle disease business will receive comparable offers from Servier, ensuring continuity of operations and future commercial execution, reflecting a commitment to talent retention and strategic integration.
See More
Biotech Fund Sells Erasca Stake After 700% Rally
- Share Reduction Details: Paradigm Biocapital Advisors disclosed the sale of 3,766,393 shares of Erasca in Q1 2026, valued at approximately $44.52 million, indicating a cautious approach to market volatility.
- Holding Proportion Change: Following this sale, Paradigm's stake in Erasca now represents 3.44% of its 13F AUM, reflecting a relative decline in importance within its portfolio and suggesting a reallocation towards other investments.
- Stock Performance: As of May 14, 2026, Erasca shares were priced at $10.37, marking a remarkable 716.5% increase over the past year, significantly outperforming the S&P 500 by 689.24 percentage points, demonstrating strong market confidence in its potential products.
- Investment Risk Advisory: Despite promising early clinical trial results, a recent incident involving a patient death led to a 46% drop in stock price in a single day, highlighting the high-risk nature of biotech investments and the need for investors to carefully assess timing.
See More
Achieve Life Sciences Appoints Three Senior Executives
- Executive Appointments: Achieve Life Sciences has appointed Christopher Martin to its Board of Directors, Mark Zappia as Senior Vice President of Commercial, and Jim Willis as Vice President of Sales, all of whom bring successful commercial experience from Verona Pharma, which is expected to drive the company towards commercialization.
- Financing Context: These appointments come on the heels of Achieve securing up to $354 million in financing, including $180 million upfront and up to $174 million from milestone-based warrants tied to FDA approval, demonstrating the company's commitment to advancing cytisinicline's commercialization.
- Market Potential: Cytisinicline could become the first new smoking cessation therapy in over two decades and the first ever for vaping cessation, addressing the urgent needs of approximately 25 million smokers and 18 million e-cigarette users in the U.S., indicating significant market potential.
- Leadership Confidence: New CEO Andrew D. Goldberg stated that the addition of these executives is one of the most consequential decisions of his tenure, reflecting Achieve's strategic positioning to tackle public health issues and enhancing confidence in the company's future growth.
See More
Cytokinetics' Heart Drug Trial Success Boosts Stock
- Significant Trial Results: Cytokinetics' Aficamten met primary endpoints in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, showing substantial improvements in health-related quality of life and exercise capacity, indicating the drug's efficacy and market potential.
- Stock Price Surge: Following the trial results, Cytokinetics' shares soared over 16% on Tuesday, reaching their highest level in over two years, reflecting strong investor enthusiasm for the drug's prospects.
- Analyst Price Target Increase: Truist raised its price target for Cytokinetics from $92 to $106 while maintaining a 'Buy' rating, signaling increased market confidence in the company's growth potential.
- Competitive Landscape Analysis: Despite Cytokinetics' strong performance, analysts noted that Edgewise's EDG-7500 may be better positioned for treating hypertrophic cardiomyopathy, highlighting the competitive intensity and future market challenges in this therapeutic area.
See More
Edgewise Grants Stock Options to New Employees
- Stock Option Grant: On May 29, 2026, Edgewise Therapeutics granted a total of 74,000 inducement stock options to four new non-executive employees, aimed at attracting talent and strengthening the team.
- Exercise Price Setting: Each inducement stock option has an exercise price of $34.16 per share, equal to the closing price of Edgewise common stock on the grant date, ensuring alignment of employee interests with those of shareholders.
- Vesting Arrangement: The vesting schedule for these stock options stipulates that 25% will vest on each employee's one-year anniversary, with the remaining shares vesting monthly, thereby incentivizing continued contributions during employment.
- Compliance Assurance: This stock option grant complies with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's strategic considerations and commitment to attracting and retaining key talent.
See More
Servier Acquires Edgewise's Muscular Dystrophy Operations
- Significant Deal Size: Servier's acquisition of Edgewise Therapeutics' muscular dystrophy operations for $2.65 billion, including the lead drug Sevasemten, is expected to close in Q3 2026, indicating Servier's strategic expansion in rare neuromuscular disorders.
- Stock Surge: Edgewise Therapeutics (EWTX) shares soared over 20% on Monday, potentially marking the largest single-day gain in six months, reflecting strong market sentiment towards the deal, and if it closes at current levels, it could push the stock to a record high.
- Drug Development Outlook: Sevasemten, an investigational oral therapy designed to protect muscles from contraction-related damage, is currently undergoing pivotal trials for Becker muscular dystrophy and a Phase 2 study for Duchenne muscular dystrophy, addressing a significant unmet need in the market with no approved treatments available.
- Positive Safety Data: The MESA extension study indicates that Sevasemten maintained stable physical function in Becker muscular dystrophy patients for up to 3.5 years, with a favorable cardiac safety profile over 12 months, showing improved cardiac function in some patients, thereby enhancing the drug's market appeal.
See More
Edgewise to Sell Muscle Disease Business for $1.55 Billion
- Significant Transaction Value: Edgewise Therapeutics has entered into an agreement with Servier to sell its muscle disease business for $1.55 billion in upfront cash, with potential milestone payments of up to $1.1 billion, leading to a total potential consideration of $2.65 billion, which will significantly enhance Edgewise's financial flexibility.
- Strategic Focus Shift: Following the transaction, Edgewise will pivot to focus on cardiovascular therapies, developing drugs such as EDG-7500 and EDG-15400, which is expected to accelerate the unlocking of its cardiovascular pipeline's potential and enhance its competitive position in the market.
- Clinical Data Reporting Plans: Edgewise plans to report 12-week data from the CIRRUS-HCM trial in Q2 2026, which will provide critical insights for the further development of its cardiac drugs, thereby advancing its clinical progress.
- Employee Transition Assurance: All Edgewise employees supporting the muscle disease business will receive comparable offers from Servier, ensuring continuity of operations and future commercial execution, reflecting a commitment to talent retention and strategic integration.
See More
Biotech Fund Sells Erasca Stake After 700% Rally
- Share Reduction Details: Paradigm Biocapital Advisors disclosed the sale of 3,766,393 shares of Erasca in Q1 2026, valued at approximately $44.52 million, indicating a cautious approach to market volatility.
- Holding Proportion Change: Following this sale, Paradigm's stake in Erasca now represents 3.44% of its 13F AUM, reflecting a relative decline in importance within its portfolio and suggesting a reallocation towards other investments.
- Stock Performance: As of May 14, 2026, Erasca shares were priced at $10.37, marking a remarkable 716.5% increase over the past year, significantly outperforming the S&P 500 by 689.24 percentage points, demonstrating strong market confidence in its potential products.
- Investment Risk Advisory: Despite promising early clinical trial results, a recent incident involving a patient death led to a 46% drop in stock price in a single day, highlighting the high-risk nature of biotech investments and the need for investors to carefully assess timing.
See More
Achieve Life Sciences Appoints Three Senior Executives
- Executive Appointments: Achieve Life Sciences has appointed Christopher Martin to its Board of Directors, Mark Zappia as Senior Vice President of Commercial, and Jim Willis as Vice President of Sales, all of whom bring successful commercial experience from Verona Pharma, which is expected to drive the company towards commercialization.
- Financing Context: These appointments come on the heels of Achieve securing up to $354 million in financing, including $180 million upfront and up to $174 million from milestone-based warrants tied to FDA approval, demonstrating the company's commitment to advancing cytisinicline's commercialization.
- Market Potential: Cytisinicline could become the first new smoking cessation therapy in over two decades and the first ever for vaping cessation, addressing the urgent needs of approximately 25 million smokers and 18 million e-cigarette users in the U.S., indicating significant market potential.
- Leadership Confidence: New CEO Andrew D. Goldberg stated that the addition of these executives is one of the most consequential decisions of his tenure, reflecting Achieve's strategic positioning to tackle public health issues and enhancing confidence in the company's future growth.
See More
Cytokinetics' Heart Drug Trial Success Boosts Stock
- Significant Trial Results: Cytokinetics' Aficamten met primary endpoints in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, showing substantial improvements in health-related quality of life and exercise capacity, indicating the drug's efficacy and market potential.
- Stock Price Surge: Following the trial results, Cytokinetics' shares soared over 16% on Tuesday, reaching their highest level in over two years, reflecting strong investor enthusiasm for the drug's prospects.
- Analyst Price Target Increase: Truist raised its price target for Cytokinetics from $92 to $106 while maintaining a 'Buy' rating, signaling increased market confidence in the company's growth potential.
- Competitive Landscape Analysis: Despite Cytokinetics' strong performance, analysts noted that Edgewise's EDG-7500 may be better positioned for treating hypertrophic cardiomyopathy, highlighting the competitive intensity and future market challenges in this therapeutic area.
See More
